<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01326845</url>
  </required_header>
  <id_info>
    <org_study_id>CICL670A2417</org_study_id>
    <secondary_id>2011-001077-13</secondary_id>
    <nct_id>NCT01326845</nct_id>
  </id_info>
  <brief_title>Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study</brief_title>
  <acronym>MACS1574</acronym>
  <official_title>A Multicenter, Randomized, Comparative Study of Different Deferasirox Administration Regimens on Gastrointestinal (GI) Tolerability in Low or Intermediate (Int-1) Risk MDS Myelodysplastic Syndrome Patients With Transfusional Iron Overload.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate and compare the frequency and severity of GI
      adverse events in different dose administration regimens. The patient population consists of
      low or intermediate (int-1) risk myelodysplastic syndrome (MDS) patients with transfusional
      iron overload. The study patients are randomized to either a morning dose of 20 mg/kg/day
      deferasirox or an evening dose of the same. Patients are then followed up for 6 months for
      any GI events and are assessed using patient reported outcomes tools e.g. a patient diary.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The trial was terminated due to insufficient enrollment.
  </why_stopped>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the Frequency of Overall Newly Occurring GI Adverse Events (AEs) in the Two Treatment Arms</measure>
    <time_frame>3 months</time_frame>
    <description>Study was prematurely terminated and not powered for efficacy. Frequency of GI AEs during the overall study period is available in the AE tables reported in the safety section.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in Frequency of Overall Newly Occurring GI AEs Between the Two Treatment Groups at Month 6.</measure>
    <time_frame>6 months</time_frame>
    <description>Study was prematurely terminated and not powered for efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Frequency of Specific Commonly Reported GI AEs Between the Two Treatment Groups</measure>
    <time_frame>months 3 and 6.</time_frame>
    <description>Study was prematurely terminated and not powered for efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Severity of Overall GI AEs Between the Two Treatment Groups</measure>
    <time_frame>months 3 and 6.</time_frame>
    <description>Study was prematurely terminated and not powered for efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Severity of Specific Commonly Reported GI Symptoms Between the Two Treatment Groups</measure>
    <time_frame>months 3 and 6</time_frame>
    <description>Study was prematurely terminated and not powered for efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Frequency and Severity of All Non-GI AEs Between the Two Treatment Groups</measure>
    <time_frame>months 3 and 6</time_frame>
    <description>Study was prematurely terminated and not powered for efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Difference Between the Time From Baseline to the First Occurrence of GI AEs Between the Two Treatment Groups</measure>
    <time_frame>3 months, 6 months</time_frame>
    <description>Study was prematurely terminated and not powered for efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Severity of GI Symptoms, Bowel Habits and Level of Satisfaction From the Patient's Perspective Between the Two Treatment Groups</measure>
    <time_frame>3 months, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Reducing Serum Ferritin After Each Month of Study Drug Administration Between the Two Groups</measure>
    <time_frame>3 months, 6 months</time_frame>
    <description>Study was prematurely terminated and not powered for efficacy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Transfusional Iron Overload</condition>
  <arm_group>
    <arm_group_label>Deferasirox am</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deferasirox 20 mg/kg/day taken in the morning, 30 minutes before food</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deferasirox pm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deferasirox 20 mg/kg/day taken in the evening, no less than 2 hours after the last food intake or at least 30 minutes before the evening meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferasirox</intervention_name>
    <arm_group_label>Deferasirox am</arm_group_label>
    <arm_group_label>Deferasirox pm</arm_group_label>
    <other_name>ICL670</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent prior to any screening procedures

          -  Male or female patients ≥ 18 years of age

          -  Patient must weigh between 45-135 kg

          -  Patients with low or intermediate (int-1) risk MDS, as determined by IPSS score or RA,
             RARS by WHO criteria. IPSS must be confirmed by a bone marrow examination within 6
             months prior to study entry and must be hematologically stable

        Deferasirox naïve:

        Sexually active pre-menopausal female patients must use double-barrier contraception, oral
        contraceptive plus barrier contraceptive, or must have undergone clinically documented
        total hysterectomy and/or oophorectomy, tubal ligation

        Exclusion Criteria:

          -  History or current GI disease

          -  Systemic diseases which could prevent study treatments

          -  Left ventricular ejection fraction&lt; 50 % by echo cardiography

          -  Serum creatinine &gt; 1.2 x ULN at screening

          -  Platelet counts &lt; 25x 109/L except in cases where guidance is already given in the
             local deferasirox label

          -  AST or ALT &gt; 2.5 xULN at screening

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caen</city>
        <state>Cedex</state>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Limoges cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pessac Cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alessandria</city>
        <state>AL</state>
        <zip>15100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bloemfontein</city>
        <zip>901</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>South Africa</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>China</country>
    <country>Israel</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2011</study_first_submitted>
  <study_first_submitted_qc>March 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2011</study_first_posted>
  <results_first_submitted>September 11, 2013</results_first_submitted>
  <results_first_submitted_qc>September 11, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 15, 2013</results_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastrointestinal adverse events,</keyword>
  <keyword>myelodysplastic syndrome,</keyword>
  <keyword>transfusional iron overload diarrhea,</keyword>
  <keyword>constipation abdominal pain,</keyword>
  <keyword>vomiting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Iron Overload</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferasirox</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Deferasirox am</title>
          <description>Deferasirox 20 mg/kg/day taken in the morning, 30 minutes before food</description>
        </group>
        <group group_id="P2">
          <title>Deferasirox pm</title>
          <description>Deferasirox 20 mg/kg/day taken in the evening, no less than 2 hours after the last food intake or at least 30 minutes before the evening meal</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Study terminated early</participants>
                <participants group_id="P2" count="0">Study terminated early</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Administrative Problems</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Misisng</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Deferasirox am</title>
          <description>Deferasirox 20 mg/kg/day taken in the morning, 30 minutes before food</description>
        </group>
        <group group_id="B2">
          <title>Deferasirox pm</title>
          <description>Deferasirox 20 mg/kg/day taken in the evening, no less than 2 hours after the last food intake or at least 30 minutes before the evening meal</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.7" spread="7.5"/>
                    <measurement group_id="B2" value="71.6" spread="8.65"/>
                    <measurement group_id="B3" value="70.5" spread="7.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference in the Frequency of Overall Newly Occurring GI Adverse Events (AEs) in the Two Treatment Arms</title>
        <description>Study was prematurely terminated and not powered for efficacy. Frequency of GI AEs during the overall study period is available in the AE tables reported in the safety section.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deferasirox am</title>
            <description>Deferasirox 20 mg/kg/day taken in the morning, 30 minutes before food</description>
          </group>
          <group group_id="O2">
            <title>Deferasirox pm</title>
            <description>Deferasirox 20 mg/kg/day taken in the evening, no less than 2 hours after the last food intake or at least 30 minutes before the evening meal</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in the Frequency of Overall Newly Occurring GI Adverse Events (AEs) in the Two Treatment Arms</title>
          <description>Study was prematurely terminated and not powered for efficacy. Frequency of GI AEs during the overall study period is available in the AE tables reported in the safety section.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Frequency of Overall Newly Occurring GI AEs Between the Two Treatment Groups at Month 6.</title>
        <description>Study was prematurely terminated and not powered for efficacy.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deferasirox am</title>
            <description>Deferasirox 20 mg/kg/day taken in the morning, 30 minutes before food</description>
          </group>
          <group group_id="O2">
            <title>Deferasirox pm</title>
            <description>Deferasirox 20 mg/kg/day taken in the evening, no less than 2 hours after the last food intake or at least 30 minutes before the evening meal</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Frequency of Overall Newly Occurring GI AEs Between the Two Treatment Groups at Month 6.</title>
          <description>Study was prematurely terminated and not powered for efficacy.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Frequency of Specific Commonly Reported GI AEs Between the Two Treatment Groups</title>
        <description>Study was prematurely terminated and not powered for efficacy.</description>
        <time_frame>months 3 and 6.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deferasirox am</title>
            <description>Deferasirox 20 mg/kg/day taken in the morning, 30 minutes before food</description>
          </group>
          <group group_id="O2">
            <title>Deferasirox pm</title>
            <description>Deferasirox 20 mg/kg/day taken in the evening, no less than 2 hours after the last food intake or at least 30 minutes before the evening meal</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Frequency of Specific Commonly Reported GI AEs Between the Two Treatment Groups</title>
          <description>Study was prematurely terminated and not powered for efficacy.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Severity of Overall GI AEs Between the Two Treatment Groups</title>
        <description>Study was prematurely terminated and not powered for efficacy.</description>
        <time_frame>months 3 and 6.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deferasirox am</title>
            <description>Deferasirox 20 mg/kg/day taken in the morning, 30 minutes before food</description>
          </group>
          <group group_id="O2">
            <title>Deferasirox pm</title>
            <description>Deferasirox 20 mg/kg/day taken in the evening, no less than 2 hours after the last food intake or at least 30 minutes before the evening meal</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Severity of Overall GI AEs Between the Two Treatment Groups</title>
          <description>Study was prematurely terminated and not powered for efficacy.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Severity of Specific Commonly Reported GI Symptoms Between the Two Treatment Groups</title>
        <description>Study was prematurely terminated and not powered for efficacy.</description>
        <time_frame>months 3 and 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deferasirox am</title>
            <description>Deferasirox 20 mg/kg/day taken in the morning, 30 minutes before food</description>
          </group>
          <group group_id="O2">
            <title>Deferasirox pm</title>
            <description>Deferasirox 20 mg/kg/day taken in the evening, no less than 2 hours after the last food intake or at least 30 minutes before the evening meal</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Severity of Specific Commonly Reported GI Symptoms Between the Two Treatment Groups</title>
          <description>Study was prematurely terminated and not powered for efficacy.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Frequency and Severity of All Non-GI AEs Between the Two Treatment Groups</title>
        <description>Study was prematurely terminated and not powered for efficacy.</description>
        <time_frame>months 3 and 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deferasirox am</title>
            <description>Deferasirox 20 mg/kg/day taken in the morning, 30 minutes before food</description>
          </group>
          <group group_id="O2">
            <title>Deferasirox pm</title>
            <description>Deferasirox 20 mg/kg/day taken in the evening, no less than 2 hours after the last food intake or at least 30 minutes before the evening meal</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Frequency and Severity of All Non-GI AEs Between the Two Treatment Groups</title>
          <description>Study was prematurely terminated and not powered for efficacy.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Difference Between the Time From Baseline to the First Occurrence of GI AEs Between the Two Treatment Groups</title>
        <description>Study was prematurely terminated and not powered for efficacy.</description>
        <time_frame>3 months, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deferasirox am</title>
            <description>Deferasirox 20 mg/kg/day taken in the morning, 30 minutes before food</description>
          </group>
          <group group_id="O2">
            <title>Deferasirox pm</title>
            <description>Deferasirox 20 mg/kg/day taken in the evening, no less than 2 hours after the last food intake or at least 30 minutes before the evening meal</description>
          </group>
        </group_list>
        <measure>
          <title>the Difference Between the Time From Baseline to the First Occurrence of GI AEs Between the Two Treatment Groups</title>
          <description>Study was prematurely terminated and not powered for efficacy.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Severity of GI Symptoms, Bowel Habits and Level of Satisfaction From the Patient's Perspective Between the Two Treatment Groups</title>
        <time_frame>3 months, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deferasirox am</title>
            <description>Deferasirox 20 mg/kg/day taken in the morning, 30 minutes before food</description>
          </group>
          <group group_id="O2">
            <title>Deferasirox pm</title>
            <description>Deferasirox 20 mg/kg/day taken in the evening, no less than 2 hours after the last food intake or at least 30 minutes before the evening meal</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Severity of GI Symptoms, Bowel Habits and Level of Satisfaction From the Patient's Perspective Between the Two Treatment Groups</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Reducing Serum Ferritin After Each Month of Study Drug Administration Between the Two Groups</title>
        <description>Study was prematurely terminated and not powered for efficacy.</description>
        <time_frame>3 months, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deferasirox am</title>
            <description>Deferasirox 20 mg/kg/day taken in the morning, 30 minutes before food</description>
          </group>
          <group group_id="O2">
            <title>Deferasirox pm</title>
            <description>Deferasirox 20 mg/kg/day taken in the evening, no less than 2 hours after the last food intake or at least 30 minutes before the evening meal</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Reducing Serum Ferritin After Each Month of Study Drug Administration Between the Two Groups</title>
          <description>Study was prematurely terminated and not powered for efficacy.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ICL am</title>
          <description>ICL am</description>
        </group>
        <group group_id="E2">
          <title>ICL pm</title>
          <description>ICL pm</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lyme disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigators are NOT employed by the organization sponsoring the study. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.
The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

